A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Completed · Phase 2 · Has a placebo group

Conditions studied: Obesity or Overweight

In brief

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

Key facts

Study ID

NCT06862791

Run by

AstraZeneca

People needed

377

Starts

2025-02-18

Expected to finish

2026-05-11

Last updated by the study team

2026-06-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be 18 to 75 years of age inclusive.
• BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity.
• A stable, self-reported body weight for 3 months prior to screening.
• Male and female participants: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
• Capable of giving signed informed consent.

You may not qualify if…

• History of any clinically important disease or disorder, which, in the opinion of the Investigator, may put the participant at risk.
• History or presence of GI, renal, hepatic disease.
• Previous or planned bariatric surgery or fitting of a weight loss device.
• Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome.
• History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control.
• HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L).
• Significant gastric and hepatobiliary disease.
• History of acute or chronic pancreatitis or pancreatic amylase or lipase > 2 × ULN at screening.
• History of psychosis or bipolar disorder.
• History of major depressive disorder within the 2 years prior to screening or depression.
• Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening.
• Vulnerable populations

Where it is running

• Research Site — Vestavia Hills, Alabama, United States
• Research Site — Cerritos, California, United States
• Research Site — Escondido, California, United States
• Research Site — Huntington Park, California, United States
• Research Site — Lincoln, California, United States
• Research Site — Sacramento, California, United States
• Research Site — Waterbury, Connecticut, United States
• Research Site — Palm Harbor, Florida, United States
• Research Site — Decatur, Georgia, United States
• Research Site — Stockbridge, Georgia, United States
• Research Site — Champaign, Illinois, United States
• Research Site — South Bend, Indiana, United States
• Research Site — Valparaiso, Indiana, United States
• Research Site — Sioux City, Iowa, United States
• Research Site — Southfield, Michigan, United States
• Research Site — Missoula, Montana, United States
• Research Site — Omaha, Nebraska, United States
• Research Site — Albuquerque, New Mexico, United States
• Research Site — Fargo, North Dakota, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Columbus, Ohio, United States
• Research Site — Tulsa, Oklahoma, United States
• Research Site — Medford, Oregon, United States
• Research Site — Kingsport, Tennessee, United States
• Research Site — Dothan, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.